Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Fluvoxamine in the Treatment of Patients with COVID-19

Assanovich et al., Psychiatry, Psychotherapy and Clinical Psychology, doi:10.34883/PI.2021.12.2.007
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
27th treatment shown to reduce risk in November 2021
 
*, now with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
5,000+ studies for 104 treatments. c19early.org
Report on the use of fluvoxamine for COVID-19 noting that "patients with COVID-19 taking fluvoxamine did not report clinical complications of coronavirus infection". Only the abstract is currently available.
Assanovich et al., 29 Jun 2021, peer-reviewed, 1 author.
This PaperFluvoxamineAll
{ 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T05:29:54Z', 'timestamp': 1648877394484}, 'reference-count': 25, 'publisher': 'Professionals Publications', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 6, 4]]}, 'abstract': '<jats:p>Наряду с легкими и другими внутренними органами COVID-19 поражает и центральную ' 'нервную систему. Воспалительные реакции, секреция цитокинов в головном мозге вызывают у ' 'большинства пациентов тревожные и депрессивные симптомы, нарушения сна. Психические ' 'расстройства связаны и с психосоциальными факторами пандемии. Для купирования ' 'психопатологических симптомов при COVID-19 часто используются антидепрессанты из группы ' 'селективных ингибиторов обратного захвата серотонина. Среди них особое место занимает ' 'флувоксамин. Флувоксамин помимо антидепрессивных и противотревожных эффектов проявляет четкие ' 'противовоспалительные свойства, которые реализуются посредством двух механизмов. Флувоксамин ' 'существенно повышает уровень ночного мелатонина в плазме крови. Мелатонин оказывает ' 'противовоспалительное, антиоксидантное и нормализующее хронобиологическое действие. Второй ' 'механизм связан с тем, что флувоксамин в терапевтических дозировках активирует сигма-1 ' 'рецепторы, что предупреждает секрецию цитокинов и развитие эндоплазматического стресса. ' 'Пациенты с COVID-19, принимавшие флувоксамин, не отмечали клинических осложнений ' 'коронавирусной инфекции.</jats:p>\n' ' ' '<jats:p>COVID-19 affects central nervous system along with lungs and other internal organs. ' 'Inflammatory reactions, secretion of cytokines in brain cause anxiety and depressive ' 'symptoms, sleep disturbances in most patients. Mental disorders are also associated with ' 'psychosocial factors of the pandemic. SSRI antidepressants are often used to relieve ' 'psychopathological symptoms in COVID-19. Among them, fluvoxamine occupies a special place. ' 'Fluvoxamine, in addition to antidepressant and anti-anxiety effects, exhibits clear ' 'anti-inflammatory properties, which are realized through two mechanisms. Fluvoxamine ' 'significantly increases the level of nocturnal melatonin in blood plasma. Melatonin has ' 'anti-inflammatory, antioxidant and chronobiological normalizing effects. The second mechanism ' 'is associated with the fact that fluvoxamine in therapeutic dosages activates sigma-1 ' 'receptors, which prevents secretion of cytokines and development of endoplasmic stress. ' 'Patients with COVID-19 taking fluvoxamine did not report clinical complications of ' 'coronavirus infection.</jats:p>', 'DOI': '10.34883/pi.2021.12.2.007', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T10:40:46Z', 'timestamp': 1645699246000}, 'page': '260-268', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Fluvoxamine in the Treatment of Patients with COVID-19', 'prefix': '10.34883', 'author': [{'given': 'М.А.', 'family': 'Ассанович', 'sequence': 'first', 'affiliation': []}], 'member': '34055', 'reference': [ { 'key': '1', 'doi-asserted-by': 'crossref', 'unstructured': 'Cullen W., Gulati G., Kelly B.D. (2020) Mental health in the COVID-19 ' 'pandemic. QJM : monthly journal of the Association of Physicians, vol. ' '113, no 5, pp. 311–312.', 'DOI': '10.1093/qjmed/hcaa110'}, { 'key': '2', 'doi-asserted-by': 'crossref', 'unstructured': 'Orsini A., Corsi M., Santangelo A., Riva A. (2020) Challenges and ' 'management of neurological and psychiatric manifestations in SARS-CoV-2 ' '(COVID-19) patients. Neurological Sciences, vol. 41, pp. 2353–2366.', 'DOI': '10.1007/s10072-020-04544-w'}, { 'key': '3', 'doi-asserted-by': 'crossref', 'unstructured': 'Bouças A.P., Rheinheimer J., Lagopoulos J. (2020) Why Severe COVID-19 ' 'Patients Are at Greater Risk of Developing Depression: A Molecular ' 'Perspective. Neuroscientist (electronic journal). Available at: ' 'https://journals.sagepub.com/doi/10.1177/1073858420967892?url_ver=Z39.88- ' '2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed ' '(accesed 5 May 2021).', 'DOI': '10.1177/1073858420967892'}, { 'key': '4', 'doi-asserted-by': 'crossref', 'unstructured': 'Schiepers O.J.G., Wichers M.C., Maes M. (2005) Cytokines and major ' 'depression. Progress in Neuro-Psychopharmacology and Biological ' 'Psychiatry, vol. 29, pp. 201–217.', 'DOI': '10.1016/j.pnpbp.2004.11.003'}, { 'key': '5', 'doi-asserted-by': 'crossref', 'unstructured': 'Villoutreix B.O., Beaune P.H., Tamouza R. (2020) Prevention of COVID-19 ' 'by drug repurposing: rationale from drugs prescribed for mental ' 'disorders. Drug Discovery Today, vol. 25, pp.1287–1290.', 'DOI': '10.1016/j.drudis.2020.06.022'}, { 'key': '6', 'doi-asserted-by': 'crossref', 'unstructured': 'Lemaitre F., Solas C., Grégoire M. (2020) Potential drug–drug ' 'interactions associated with drugs currently proposed for COVID-19 ' 'treatment in patients receiving other treatments. Fundamental and ' 'Clinical Pharmacology, vol. 34, pp. 530–547.', 'DOI': '10.1111/fcp.12586'}, { 'key': '7', 'doi-asserted-by': 'crossref', 'unstructured': 'Bishara D., Kalafatis C., Taylor D. (2020) Emerging and experimental ' 'treatments for COVID-19 and drug interactions with psychotropic agents. ' 'Therapeutic Advances in Psychopharmacology (electronic journal), vol. ' '10. Available at: https://journals.sagepub.com/doi/ ' 'full/10.1177/2045125320935306 (Accessed 5 May 2021).', 'DOI': '10.1177/2045125320935306'}, { 'key': '8', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang K., Zhou X., Liu H. (2021) Treatment concerns for psychiatric ' 'symptoms in patients with COVID-19 with or without psychiatric ' 'disorders. British Journal of Psychiatry, vol. 217, pp. 351.', 'DOI': '10.1192/bjp.2020.84'}, { 'key': '9', 'doi-asserted-by': 'crossref', 'unstructured': 'Hashimoto K. (2021) Repurposing of CNS drugs to treat COVID-19 ' 'infection: targeting the sigma-1 receptor. European Archives of ' 'Psychiatry and Clinical Neuroscience, vol. 271, pp. 249–258.', 'DOI': '10.1007/s00406-020-01231-x'}, { 'key': '10', 'doi-asserted-by': 'crossref', 'unstructured': 'Rohilla J., Tak P., Jhanwar S. (2020) Primary care physician’s approach ' 'for mental health impact of COVID-19. Journal of Family Medicine and ' 'Primary Care (electronic journal), vol. 9. Available at: ' 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567264/ (Accessed 5 May ' '2021).', 'DOI': '10.4103/jfmpc.jfmpc_513_20'}, { 'key': '11', 'doi-asserted-by': 'crossref', 'unstructured': 'Park E.J., Lee J.H., Jeong D.C. (2015) Natural killer cell activity in ' 'patients with major depressive disorder treated with escitalopram. ' 'International Immunopharmacology, vol. 28, pp. 409–413.', 'DOI': '10.1016/j.intimp.2015.06.031'}, { 'key': '12', 'doi-asserted-by': 'crossref', 'unstructured': 'Omori I.M., Watanabe N., Nakagawa A. (2010) Fluvoxamine versus other ' 'anti-depressive agents for depression. Cochrane Database of Systematic ' 'Reviews. Available at: ' 'https://www.cochrane.org/CD006114/DEPRESSN_fluvoxamine-versus-other-anti-depressive-agents-for- ' 'depression#:~:text=Fluvoxamine versus other anti-depressive agents for ' 'depression Major,symptoms%2C inappropriate guilt and morbid thoughts of ' 'death (Accessed 5 May 2021).', 'DOI': '10.1002/14651858.CD006114.pub2'}, { 'key': '13', 'unstructured': 'Irons J. (2005) Fluvoxamine in the treatment of anxiety disorders. ' 'Neuropsychiatric disease and treatment, vol. 1, pp. 289–299.'}, { 'key': '14', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang R., Wang X., Ni L. (2020) COVID-19: Melatonin as a potential ' 'adjuvant treatment. Life Sciences (electronic journal). Available at: ' 'https://www. sciencedirect.com/science/article/abs/pii/S0024320520303313 ' '(Accessed 5 May 2021).', 'DOI': '10.1016/j.lfs.2020.117583'}, { 'key': '15', 'doi-asserted-by': 'crossref', 'unstructured': 'Shneider A., Kudriavtsev A., Vakhrusheva A. (2020) Can melatonin reduce ' 'the severity of COVID-19 pandemic? International Reviews of Immunology, ' 'vol. 39, pp. 153–162.', 'DOI': '10.1080/08830185.2020.1756284'}, { 'key': '16', 'doi-asserted-by': 'crossref', 'unstructured': 'Acuña-Castroviejo D., Escames G., Figueira J.C. (2020) Clinical trial to ' 'test the efficacy of melatonin in COVID-19. Journal of Pineal Research, ' 'vol. 69, pp. 1–4.', 'DOI': '10.1111/jpi.12683'}, { 'key': '17', 'doi-asserted-by': 'crossref', 'unstructured': 'Reiter R.J., Abreu-Gonzalez P., Marik P.E. (2020) Therapeutic Algorithm ' 'for Use of Melatonin in Patients With COVID-19. Frontiers in Medicine, ' 'vol. 7. Available at: ' 'https://www.frontiersin.org/articles/10.3389/fmed.2020.00226/full ' '(Accessed 5 May 2021).', 'DOI': '10.3389/fmed.2020.00226'}, { 'key': '18', 'doi-asserted-by': 'crossref', 'unstructured': 'Von Bahr C., Ursing C., Yasui N. (2000) Fluvoxamine but not citalopram ' 'increases serum melatonin in healthy subjects – An indication that ' 'cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European ' 'Journal of Clinical Pharmacology, vol. 56, pp. 123–127.', 'DOI': '10.1007/s002280050729'}, { 'key': '19', 'doi-asserted-by': 'crossref', 'unstructured': 'Anderson G.M. (2021) Fluvoxamine, melatonin and COVID-19. ' 'Psychopharmacology, vol. 238, no 2, pp. 611.', 'DOI': '10.1007/s00213-020-05753-z'}, { 'key': '20', 'doi-asserted-by': 'crossref', 'unstructured': 'Dallé E., Daniels W.M.U., Mabandla M V. (2017) Fluvoxamine maleate ' 'normalizes striatal neuronal inflammatory cytokine activity in a ' 'Parkinsonian rat model associated with depression. Behavioural Brain ' 'Research, vol. 316, pp. 189–196.', 'DOI': '10.1016/j.bbr.2016.08.005'}, { 'key': '21', 'doi-asserted-by': 'crossref', 'unstructured': 'Yoshimura R., Katsuki A., Atake K. (2017) Influence of fluvoxamine on ' 'plasma interleukin-6 or clinical improvement in patients with major ' 'depressive disorder. Neuropsychiatric Disease and Treatment, vol. 13, ' 'pp. 437–441.', 'DOI': '10.2147/NDT.S123121'}, { 'key': '22', 'doi-asserted-by': 'crossref', 'unstructured': 'Troncone L.R. (2020) COVID-19, cytokine storm and sigma-1 receptors: ' 'potential treatments at hand? Authorea, vol. 19, pp. 1–3.', 'DOI': '10.22541/au.159335613.31156244'}, { 'key': '23', 'doi-asserted-by': 'crossref', 'unstructured': 'Hindmarch I., Hashimoto K. (2010) Cognition and depression: The effects ' 'of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human ' 'Psychopharmacology, vol. 25, pp. 193–200.', 'DOI': '10.1002/hup.1106'}, { 'key': '24', 'doi-asserted-by': 'crossref', 'unstructured': 'Lenze E.J., Mattar C., Zorumski C.F. (2020) Fluvoxamine vs Placebo and ' 'Clinical Deterioration in Outpatients with Symptomatic COVID-19: A ' 'Randomized Clinical Trial. Journal of the American Medical Association, ' 'vol. 324, pp. 2292–2300.', 'DOI': '10.1001/jama.2020.22760'}, { 'key': '25', 'doi-asserted-by': 'crossref', 'unstructured': 'Seftel D., Boulware D.R. (2021) Prospective Cohort of Fluvoxamine for ' 'Early Treatment of Coronavirus Disease 19. Open Forum Infectious ' 'Diseases, vol. 8, pp. 1–3.', 'DOI': '10.1093/ofid/ofab050'}], 'container-title': 'Психиатрия, психотерапия и клиническая психология', 'original-title': ['Флувоксамин в терапии пациентов с COVID-19'], 'language': 'ru', 'deposited': { 'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T10:42:00Z', 'timestamp': 1645699320000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://psihea.recipe.by/ru/?editions=2021-tom-12-n-2&group_id=item_1&article_id=line_1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6, 4]]}, 'references-count': 25, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2021, 6, 4]]}}, 'URL': 'http://dx.doi.org/10.34883/PI.2021.12.2.007', 'relation': {}, 'ISSN': ['2220-1122', '2414-2212'], 'subject': [], 'published': {'date-parts': [[2021, 6, 4]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit